查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000440

噬菌體療法和合成微生物組工程市場：預測至2034年－按產品、目標病原體、技術、應用、最終用戶和地區分類的全球分析

Phage Therapy & Synthetic Microbiome Engineering Market Forecasts to 2034 - Global Analysis By Product, By Target Pathogen, By Technology, By Application, By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球噬菌體療法和合成微生物組工程市場預計將在 2026 年達到 13 億美元，並在預測期內以 4.1% 的複合年成長率成長，到 2034 年達到 18 億美元。

噬菌體療法和合成微生物組工程利用特異性靶向細菌的噬菌體（病毒）或基因工程改造的微生物群落來治療感染疾病並恢復健康的微生物組。噬菌體療法是一種很有前景的抗生素替代方案，因為它能夠選擇性地清除有害細菌，同時保留有益微生物。合成微生物組工程利用設計的微生物群落來調節腸道或環境微生物組，以達到治療目的。這些方法利用精準微生物學和生物技術的進步來應對抗生素抗藥性問題，改善疾病治療，並支持個人化醫療。

全球抗生素抗藥性日益增強

許多細菌感染疾病對傳統抗生素的抗藥性日益增強，迫切需要尋找替代療法。噬菌體療法利用噬菌體特異性靶向並摧毀有害細菌。對於已對抗生素產生抗藥性的感染疾病，這些療法提供了一個很有前景的解決方案。隨著全球抗生素抗藥性問題的持續加劇，人們對基於噬菌體的治療方法的興趣也迅速成長。

複雜的監管核准流程

在許多國家，噬菌體療法的法律規範仍在發展中。由於這些治療方法通常需要為每位患者進行個人化配製，因此標準化和大規模臨床檢驗更加困難。監管機構要求在核准前提供大量的安全性和有效性資料。這些因素可能會延緩商業化進程並限制市場成長。

開發個人化噬菌體療法

個人化醫療利用針對特定細菌感染疾病客製化的噬菌體。基因組學和微生物組研究的進展正在推動此類標靶治療的開發。這些療法能夠在提供高度精準治療的同時，最大限度地減少對有益菌的影響。研究機構和生技公司正積極投資個人化噬菌體療法平台。隨著個人化醫療的日益普及，對患者特異性噬菌體療法的需求預計將會成長。

細菌對噬菌體療法的抗藥性

噬菌體雖然能夠適應和演化，但細菌仍能發展出針對噬菌體的防禦機制。為了維持噬菌體的有效性，需要持續監測並開發新的噬菌體菌株。這一過程會增加研發成本。此外，大規模生產和確保噬菌體製劑的穩定性在技術上也十分複雜。這些挑戰可能會影響噬菌體療法的長期應用。

新冠疫情的影響：

新冠疫情對噬菌體療法和微生物組工程領域的研究活動產生了影響。疫情初期，由於醫療系統優先應對新冠治療和疫苗研發，許多研究計畫被迫暫停。然而，疫情也凸顯了先進感染疾病治療方法的重要性。研究人員已將研究重點轉向對抗抗生素抗藥性的創新解決方案。因此，人們對噬菌體療法的研究和投資興趣持續成長。

在預測期內，抗生素抗藥性細菌細分市場預計將佔據最大的市場佔有率。

由於噬菌體療法對抗生素抗藥性細菌尤其有效，預計在預測期內，抗生素抗藥性細菌領域將佔據最大的市場佔有率。許多醫療系統正面臨多重抗藥性細菌感染疾病病例不斷增加的挑戰。噬菌體療法為這類感染疾病提供了一種標靶性強且高效的治療選擇。醫院和研究機構正積極探索噬菌體在對抗抗藥性病原體的應用。這些因素共同支撐了抗生素抗藥性細菌領域的市場主導地位。

在預測期內，製藥公司板塊預計將呈現最高的複合年成長率。

在預測期內，由於噬菌體療法研究的增加和對基於微生物組的治療方法的投資，製藥公司預計將呈現最高的成長率。這些公司正在進行臨床試驗，以開發新的噬菌體藥物。生技公司和製藥公司之間的合作也不斷加強。人們對替代抗菌療法的興趣日益濃厚，進一步推動了這一趨勢。隨著藥物研發活動的擴展，製藥公司將在市場成長中發揮重要作用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其強大的生物技術研究基礎設施和先進的醫療保健系統。許多領先的生物技術公司和研究機構正在致力於噬菌體療法的研發。政府對抗菌素抗藥性研究的資助也促進了創新。此外，該地區還擁有許多致力於微生物組療法研發的製藥公司。這些因素共同促成了北美在市場上的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健投資的增加和研發活動的活性化。中國、日本和韓國等國家正在擴大其生物技術研發能力。人們對抗生素抗藥性的日益關注也促進了新治療方法的應用。政府支持先進醫療技術的措施進一步推動了市場發展。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球噬菌體療法與合成微生物組工程市場：依產品分類

  • 治療性噬菌體製劑
  • 個人化噬菌體雞尾酒
  • 預先設計的合成噬菌體
  • 微生物組療法聯盟
  • 其他產品

第6章 全球噬菌體療法和合成微生物組工程市場：以目標病原體分類

  • 抗抗生素細菌
  • 葡萄球菌感染疾病
  • 銅綠假單胞菌感染疾病
  • 大腸桿菌感染疾病
  • 其他目標病原體

第7章 全球噬菌體療法和合成微生物組工程市場：依技術分類

  • 基於CRISPR的噬菌體工程
  • 合成生物學平台
  • 定向演化技術
  • 人工智慧驅動的噬菌體設計
  • 其他技術

第8章 全球噬菌體療法和合成微生物組工程市場：按應用分類

  • 感染疾病治療
  • 消化系統疾病
  • 皮膚和創傷護理
  • 呼吸道感染疾病
  • 其他用途

第9章 全球噬菌體療法和合成微生物組工程市場：依最終用戶分類

  • 醫院
  • 生技公司
  • 製藥公司
  • 學術研究機構
  • 動物診所
  • 農業企業
  • 其他最終用戶

第10章 全球噬菌體療法和合成微生物組工程市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Adaptive Phage Therapeutics
  • Pherecydes Pharma
  • Armata Pharmaceuticals, Inc.
  • Locus Biosciences, Inc.
  • Synthego Corporation
  • Synlogic, Inc.
  • Seres Therapeutics, Inc.
  • Second Genome, Inc.
  • Enterome SA
  • Microbiotica Ltd.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Johnson & Johnson
  • Eligo Bioscience
Product Code: SMRC34579

According to Stratistics MRC, the Global Phage Therapy & Synthetic Microbiome Engineering Market is accounted for $1.3 billion in 2026 and is expected to reach $1.8 billion by 2034 growing at a CAGR of 4.1% during the forecast period. Phage Therapy & Synthetic Microbiome Engineering involves the use of bacteriophages viruses that specifically target bacteria-and engineered microbial communities to treat infections and restore healthy microbiomes. Phage therapy selectively eliminates harmful bacteria while preserving beneficial microbes, making it a promising alternative to antibiotics. Synthetic microbiome engineering uses designed microbial consortia to modulate gut or environmental microbiomes for therapeutic purposes. These approaches address antibiotic resistance, improve disease treatment, and support personalized medicine by leveraging precision microbiology and advances in biotechnology.

Market Dynamics:

Driver:

Rising antimicrobial resistance globally

Many bacterial infections are becoming increasingly resistant to conventional antibiotics. This has created an urgent need for alternative therapeutic approaches. Phage therapy uses bacteriophages that specifically target and destroy harmful bacteria. These therapies provide a promising solution for infections that no longer respond to antibiotics. As antibiotic resistance continues to rise worldwide, interest in phage-based treatments is growing rapidly.

Restraint:

Complex regulatory approval processes

Regulatory frameworks for phage therapies are still evolving in many countries. These treatments often require customized formulations for individual patients. This makes standardization and large-scale clinical validation more challenging. Regulatory authorities require extensive safety and efficacy data before approval. These factors can delay commercialization and limit market growth.

Opportunity:

Personalized phage therapy developments

Personalized treatments use specific bacteriophages tailored to a patient's bacterial infection. Advances in genomics and microbiome research are supporting the development of such targeted therapies. These solutions can provide highly precise treatment with minimal impact on beneficial bacteria. Research institutions and biotech companies are actively investing in personalized phage therapy platforms. As personalized medicine gains popularity, demand for tailored phage therapies is expected to increase.

Threat:

Bacterial resistance to phage therapies

Although bacteriophages can adapt and evolve, bacteria may still develop defense mechanisms against them. Continuous monitoring and development of new phage strains are required to maintain effectiveness. This process can increase research and development costs. Additionally, large-scale production and stability of phage preparations can be technically complex. These challenges may affect long-term adoption of phage therapy solutions.

Covid-19 Impact:

The COVID-19 pandemic influenced research activities in the phage therapy and microbiome engineering market. During the early stages of the pandemic, many research programs were temporarily delayed. Healthcare systems prioritized COVID-19 treatment and vaccine development. However, the pandemic highlighted the importance of advanced infectious disease therapies. Researchers increased focus on innovative solutions for antimicrobial resistance. As a result, interest in phage therapy research and investment has continued to grow.

The antibiotic-resistant bacteria segment is expected to be the largest during the forecast period

The antibiotic-resistant bacteria segment is expected to account for the largest market share during the forecast period because phage therapy is particularly effective against bacteria that do not respond to antibiotics. Many healthcare systems are facing increasing cases of multidrug-resistant infections. Phage therapies offer a targeted and efficient treatment option for such infections. Hospitals and research institutions are actively studying phage applications for resistant pathogens. These factors support the dominance of the antibiotic-resistant bacteria segment.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate due to increased investment in phage therapy research and microbiome-based therapeutics. These companies are conducting clinical trials to develop new phage-based drugs. Partnerships between biotech firms and pharmaceutical companies are also increasing. Growing interest in alternative antimicrobial therapies further supports this trend. As drug development activities expand, pharmaceutical companies will play a major role in market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong biotechnology research infrastructure and advanced healthcare systems. Many leading biotech companies and research institutions are developing phage therapies. Government funding for antimicrobial resistance research also supports innovation. Additionally, the region has a strong presence of pharmaceutical companies working on microbiome-based therapeutics. These factors contribute to North America's leading position in the market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rising healthcare investments and increasing research activities are driving market growth in this region. Countries such as China, Japan, and South Korea are expanding biotechnology research capabilities. Growing awareness of antimicrobial resistance is also encouraging the adoption of new therapies. Government initiatives supporting advanced healthcare technologies further boost the market.

Key players in the market

Some of the key players in Phage Therapy & Synthetic Microbiome Engineering Market include Adaptive Phage Therapeutics, Pherecydes Pharma, Armata Pharmaceuticals, Inc., Locus Biosciences, Inc., Synthego Corporation, Synlogic, Inc., Seres Therapeutics, Inc., Second Genome, Inc., Enterome SA, Microbiotica Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson and Eligo Bioscience.

Key Developments:

In May 2025, Synthego expanded its CRISPR portfolio with the launch of GMP SpCas9, a nuclease manufactured under current Good Manufacturing Practice (cGMP) standards . This product is designed to be bundled with their GMP guide RNAs to streamline the development of CRISPR-based therapeutics for clinical studies.

In November 2023, Pherecydes Pharma company was acquired by the ERBC Group, a French preclinical Contract Research Organization (CRO). This strategic move transitioned Pherecydes from a standalone biotech into the "Phage Unit" of ERBC, aiming to leverage its expertise to offer phagogram services to hospital clients seeking personalized anti-bacterial treatments.

Products Covered:

  • Therapeutic Bacteriophage Preparations
  • Personalized Phage Cocktails
  • Engineered Synthetic Phages
  • Microbiome Therapeutic Consortia
  • Other Products

Target Pathogens Covered:

  • Antibiotic-Resistant Bacteria
  • Staphylococcus Infections
  • Pseudomonas Infections
  • E. coli Infections
  • Other Target Pathogens

Technologies Covered:

  • CRISPR-Based Phage Engineering
  • Synthetic Biology Platforms
  • Directed Evolution Techniques
  • AI-Based Phage Design
  • Other Technologies

Applications Covered:

  • Infectious Disease Treatment
  • Gastrointestinal Disorders
  • Skin & Wound Care
  • Respiratory Infections
  • Other Applications

End Users Covered:

  • Hospitals
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic & Research Institutes
  • Veterinary Clinics
  • Agricultural Enterprises
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Product

  • 5.1 Therapeutic Bacteriophage Preparations
  • 5.2 Personalized Phage Cocktails
  • 5.3 Engineered Synthetic Phages
  • 5.4 Microbiome Therapeutic Consortia
  • 5.5 Other Products

6 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Target Pathogen

  • 6.1 Antibiotic-Resistant Bacteria
  • 6.2 Staphylococcus Infections
  • 6.3 Pseudomonas Infections
  • 6.4 E. coli Infections
  • 6.5 Other Target Pathogens

7 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Technology

  • 7.1 CRISPR-Based Phage Engineering
  • 7.2 Synthetic Biology Platforms
  • 7.3 Directed Evolution Techniques
  • 7.4 AI-Based Phage Design
  • 7.5 Other Technologies

8 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Application

  • 8.1 Infectious Disease Treatment
  • 8.2 Gastrointestinal Disorders
  • 8.3 Skin & Wound Care
  • 8.4 Respiratory Infections
  • 8.5 Other Applications

9 Global Phage Therapy & Synthetic Microbiome Engineering Market, By End User

  • 9.1 Hospitals
  • 9.2 Biotechnology Companies
  • 9.3 Pharmaceutical Companies
  • 9.4 Academic & Research Institutes
  • 9.5 Veterinary Clinics
  • 9.6 Agricultural Enterprises
  • 9.7 Other End Users

10 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Adaptive Phage Therapeutics
  • 13.2 Pherecydes Pharma
  • 13.3 Armata Pharmaceuticals, Inc.
  • 13.4 Locus Biosciences, Inc.
  • 13.5 Synthego Corporation
  • 13.6 Synlogic, Inc.
  • 13.7 Seres Therapeutics, Inc.
  • 13.8 Second Genome, Inc.
  • 13.9 Enterome SA
  • 13.10 Microbiotica Ltd.
  • 13.11 Pfizer Inc.
  • 13.12 F. Hoffmann-La Roche Ltd.
  • 13.13 Novartis AG
  • 13.14 Johnson & Johnson
  • 13.15 Eligo Bioscience

List of Tables

  • Table 1 Global Phage Therapy & Synthetic Microbiome Engineering Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Product (2023-2034) ($MN)
  • Table 3 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Therapeutic Bacteriophage Preparations (2023-2034) ($MN)
  • Table 4 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Personalized Phage Cocktails (2023-2034) ($MN)
  • Table 5 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Engineered Synthetic Phages (2023-2034) ($MN)
  • Table 6 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Microbiome Therapeutic Consortia (2023-2034) ($MN)
  • Table 7 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other Products (2023-2034) ($MN)
  • Table 8 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Target Pathogen (2023-2034) ($MN)
  • Table 9 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Antibiotic-Resistant Bacteria (2023-2034) ($MN)
  • Table 10 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Staphylococcus Infections (2023-2034) ($MN)
  • Table 11 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Pseudomonas Infections (2023-2034) ($MN)
  • Table 12 Global Phage Therapy & Synthetic Microbiome Engineering Market, By E. coli Infections (2023-2034) ($MN)
  • Table 13 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other Target Pathogens (2023-2034) ($MN)
  • Table 14 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Technology (2023-2034) ($MN)
  • Table 15 Global Phage Therapy & Synthetic Microbiome Engineering Market, By CRISPR-Based Phage Engineering (2023-2034) ($MN)
  • Table 16 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Synthetic Biology Platforms (2023-2034) ($MN)
  • Table 17 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Directed Evolution Techniques (2023-2034) ($MN)
  • Table 18 Global Phage Therapy & Synthetic Microbiome Engineering Market, By AI-Based Phage Design (2023-2034) ($MN)
  • Table 19 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other Technologies (2023-2034) ($MN)
  • Table 20 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Application (2023-2034) ($MN)
  • Table 21 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Infectious Disease Treatment (2023-2034) ($MN)
  • Table 22 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Gastrointestinal Disorders (2023-2034) ($MN)
  • Table 23 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Skin & Wound Care (2023-2034) ($MN)
  • Table 24 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Respiratory Infections (2023-2034) ($MN)
  • Table 25 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other Applications (2023-2034) ($MN)
  • Table 26 Global Phage Therapy & Synthetic Microbiome Engineering Market, By End User (2023-2034) ($MN)
  • Table 27 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Hospitals (2023-2034) ($MN)
  • Table 28 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Biotechnology Companies (2023-2034) ($MN)
  • Table 29 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 30 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 31 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Veterinary Clinics (2023-2034) ($MN)
  • Table 32 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Agricultural Enterprises (2023-2034) ($MN)
  • Table 33 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.